Abstract
Venous diseases become steadily more common and severe with age, and are often accompanied by venous lymphatic oedema. We have investigated the role of glycoconjugates in this disorder and the action of procyanidols used to treat these diseases. Explants of vein wall from patients with or without venous lymphatic edema were cultured for 24 hours and the incorporation of radioactive glucosamine into total glycoconjugates and into hyaluronan was measured. The explants from patients with oedema incorporated more glucosamine than those without oedema (+42% expressed as c.p.m./mg dry weight into total glycosaminoglycans and +12% expressed as c.p.m./mg dry weight into hyaluronan). The explants from oedematous patients secreted less glycoconjugates into the culture medium than those from non-oedematous veins (-63% of total incorporated radioactivity into hyaluronan and -66% into hyaluronidase-resistant glycoconjugates). Explants placed in medium containing procyanidols (1 mg/ml, 2.8 mM) incorporated less glucosamine (-19%) and secreted more into the medium (+119%). Glycoprotein and sulphated glycosaminoglycan synthesis were mainly affected which may well explain the beneficial effect of procyanidols on vein disorders.